January 2023 in “International Journal of Trichology” Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
4 citations
,
October 2024 in “Heliyon” CYP154C7 enzyme can effectively modify steroids and is promising for commercial use.
April 2011 in “Companion Animal” Feline pododermatitis is less common in cats than in dogs.
June 2023 in “The Journal of Dermatology”
February 2022 in “Chinese Journal of Dermatology” A 36-year-old woman with worsening hair loss over 10 years was treated with various medications, and after six months, her hair loss did not worsen significantly.
TrichoSol™ effectively stabilizes various hair treatment ingredients for different durations.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
2 citations
,
April 2018 in “Natural Product Communications” Cynomorium songaricum has many health benefits and could help with hair regrowth.
8 citations
,
June 1995 in “Helvetica Chimica Acta” Compound 15a was effective in inhibiting 5α-reductase.
12 citations
,
June 2001 in “Bioorganic & Medicinal Chemistry” Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.
November 2024 in “Journal of Investigative Dermatology” Genetic changes in specific proteins contribute to hair loss in some women of African descent.
2 citations
,
July 1968 in “Experimental Biology and Medicine” Cystaselenonine causes temporary hair loss in mice by interfering with hair growth.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
15 citations
,
September 1984 in “Veterinary Clinics of North America: Small Animal Practice” The document explains various skin conditions in cats and how to diagnose and treat them.
19 citations
,
March 1987 in “International Journal of Dermatology” A drug called cimetidine can help treat hair loss in women by blocking androgen receptors. However, it's not the first choice and needs more research.
April 2026 in “Journal of Cancer” Cepharanthine shows promise as a natural anticancer treatment.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
January 2015 in “Zurich Open Repository and Archive (University of Zurich)” The supplement did not work better than a placebo for hair loss in women over 60.
8 citations
,
January 2018 in “Journal of the American Academy of Dermatology” Diphenylcyclopropenone treatment helps prevent hair loss relapse in alopecia areata patients.
114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” The new clobetasol propionate foam is effective and safe for treating alopecia areata.
6 citations
,
August 2013 in “Joint Bone Spine” Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
1 citations
,
January 2023 in “PubMed” Urtica dioica extract may help treat androgenic skin diseases by reducing a specific gene's activity.
1 citations
,
January 2025 in “Annals of Dermatology” Baricitinib is effective and safe for treating alopecia areata in Korea.
15 citations
,
June 2020 in “Processes” CMX from Centipeda minima can significantly improve hair growth in mild to moderate balding.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
June 2023 in “Indian Journal of Canine Practice” The cat fully recovered from skin issues after treatment with medication and shampoo.
5 citations
,
April 2023 in “Pharmaceuticals” The new delivery system improved hair growth in alopecia treatment.
December 2022 in “Jurnal Farmasi Klinik Base Practice” Cyclophosphamide helped 59.4% of children with steroid-resistant nephrotic syndrome but caused side effects in 40.6%.
Choose the best brow lift method based on patient needs and goals.